■ In 2019, 3-year results from the LiGHT Trial found initial selective laser trabeculoplasty (SLT) treatment provided predominantly drop-free IOP control in almost 80% of eyes newly diagnosed with ocular hypertension (OHT) and open-angle glaucoma (OAG). This was coupled with a reduced need for glaucoma and cataract surgery vs initial drop regimens. Data indicated SLT may slow progression to more advanced glaucoma.

The investigators discussed the findings from the 6-year extension in Ophthalmology. Patients initially treated with drops could have SLT to reduce medication, to avoid increasing medication, or to delay surgery. Initial SLT patients were allowed to undergo a third and final SLT before adding IOP-lowering eye drops. Gazzard and colleagues found that after 6 years of treatment, there were statistically significant lower rates of disease progression and reduced need for glaucoma and cataract surgery for eyes initially treated with SLT. “Drop-free IOP control and safety of SLT as a first-line treatment for OHT and OAG were confirmed,” they wrote.